Operating Losses Widened by Chemicals Business Development Costs and Staff Expansion
First written in FY2023-Q3. 6 of 10 entries say "Mitigated", first in FY2024-Q3. Latest entry: FY2026.
The whole theme swung hardest in 2020: 6 of 21 companies on the "Worse" side.
6 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「As a result, sales in the chemicals business increased by ¥277.321 million, or 11.6%, year on year to ¥2,669.227 million, while operating profit increased by ¥34.154 million, or 59.7%, to ¥91.331 million.」
Despite the cost burden associated with strengthening the development and sales structures, the Chemicals business posted higher revenue and profit, improving on the previous operating-loss trend. - FY2026-H1MitigatedAnnual report
「Meanwhile, development and selling expenses increased as the development and sales structures were strengthened in preparation for entering new fields such as PFAS. However, as the increase in gross profit exceeded the increase in selling, general and administrative expenses, results improved from an operating loss in the same period of the previous year, and the company recorded operating profit in the current period for the second consecutive quarter following the first quarter.」
Expenses increased as the development and sales structures were strengthened to enter new fields, but the Chemicals business improved from an operating loss to operating profit as gross profit increased. - FY2025-H1MitigatedAnnual report
「In addition, development and sales expenses increased year on year as the development and sales structures were expanded during the previous fiscal year to deepen the company's technology and strengthen communication externally. As a result, Chemicals business revenue increased by ¥80.965 million, or 8.0%, year on year to ¥1,089.319 million, while operating loss was ¥17.178 million, compared with an operating loss of ¥55.251 million in the previous interim accounting period.」
Development and selling expenses increased as the development and sales structures were expanded, but the Chemicals business's operating loss narrowed year on year as revenue increased. - FY2024-Q3MitigatedAnnual report
「The improvement in the cost ratio resulting from higher sales and a change in the sales mix exceeded the increase in selling expenses for strengthening sales activities, resulting in operating profit in the third quarter. Consequently, cumulative operating loss for the first 3 quarters narrowed, reversing the trend toward a narrower loss compared with the same period of the previous year.」
In the Chemicals business, the improvement in the cost ratio resulting from the sales mix exceeded the increase in selling expenses, and operating profit was recorded in the third quarter, causing cumulative operating loss associated with development and sales investment to narrow. - FY2024-Q2WorsenedAnnual report
「Profit margins declined mainly because the overall cost ratio for internally processed products increased, while development and selling expenses rose as a result of active investment in development and intensified sales activities aimed at expanding sales.」
In the Chemicals business, profit margins declined and operating loss widened due to higher cost ratios for internally processed products and increased expenses associated with development investment and intensified sales activities aimed at expanding sales. - FY2023WorsenedAnnual report
「We have continued to design water treatment systems using ion-exchange resins and separation membranes. We are also working with overseas manufacturers on the joint development of ion-exchange resins, and are developing products that can serve as alternatives to existing products or address specialised applications. Research and development expenses in the Chemicals business for the fiscal year amounted to ¥18.658 million, mainly for the development and testing of various ion-exchange resins and the design of liquid treatment systems.」
In the Chemicals business, development, testing and system design continued, and ¥18.658 million was recorded as research and development expenses. Due in part to insufficient orders for large-scale system projects, full-year operating loss widened to ¥49.511 million. - FY2023-Q3First statedAnnual report
「Meanwhile, operating loss increased because development costs rose as a result of more testing associated with development and increased personnel.」
In the Chemicals business, development costs increased due to more development-related testing and increased personnel, and operating loss widened from ¥2.498 million to ¥25.340 million.